Tracers / [68Ga]Ga-FAPI-04
[68Ga]Ga-FAPI-04
Also written as [68Ga]Ga-FAPI-04; [68Ga]Ga-FAPI-4; [Ga-68]Ga-FAPI-04; FAPI-04; Ga-68 FAPI-04
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 47
What it is
- Compound class
- Radiolabelled quinoline-based FAP-inhibitor (small molecule, DOTA-conjugated)
- Target / mechanism
- Fibroblast activation protein (FAP), a serine protease overexpressed on cancer-associated fibroblasts PMID 30850501
- Clinical application
- Pan-cancer imaging of tumour-stroma/fibroblast activation (evaluated across 28 cancer types) PMID 30954939
- Theranostic pair
- <a href="/tracers/lu177-fapi04/">lu177-fapi04</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | SPE | — | — | DOTA-FAPI-04 precursor | 35991604 2022 Front Chem |
| Modular-Lab Standard Eckert & Ziegler | fixed tubing | SPE | 85.5±1.4% no | — | DOTA-FAPI-4 MedChemExpress | 39050235 2024 Asia Ocean J Nucl Med Biol Automated radiosynthesis module (Modular-Lab Standard) was from Eckert & Ziegler, Germany. — The non-decay corrected (ndc) RCY for [68Ga]Ga-Pentixafor, [68Ga]Ga-FAPI-4 and [68Ga]Ga-DOTATATE were found to be...(85.5±1.4)% (n=9) |
| — | — | HPLC | — | >98% | DOTA-FAPI-04 MedChemExpress | 42691023 2026 PLoS One |
| — | — | — | — | — | — | 42591149 2026 Front Immunol |
| — | — | — | 90.2% | 96.5% | FAPI-04 | 42569132 2026 ACS Omega |
| — | — | — | — | — | — | 42318157 2026 Oncol Rev |
| — | — | SPE | — | — | FAPI-04 Huayi | 42180616 2026 Oncol Lett |
| — | — | — | — | — | — | 42115250 2026 Sci Rep |
| — | — | — | — | — | — | 41904503 2026 Breast Cancer Res |
| — | — | — | — | — | — | 41871918 2026 RMD Open |
| — | — | — | — | — | FAPI-04 | 41807884 2026 Mol Diagn Ther |
| — | — | — | — | — | — | 41692852 2026 Eur J Nucl Med Mol Imaging |
| — | vendor cassette | — | — | — | FAPI cold kit | 41689142 2026 Cancer Imaging |
| — | — | — | — | — | — | 41599688 2026 Pharmaceuticals (Basel) |
| — | — | — | — | — | — | 41515390 2025 Molecules |
| — | — | — | — | exceeded 95% | FAPI-04 MCE, MedChemExpress, USA | 41408360 2025 Cancer Imaging |
| — | — | — | — | — | — | 41344856 2026 J Nucl Med |
| — | — | — | — | — | — | 41286125 2026 Eur J Nucl Med Mol Imaging |
| — | — | SPE | — | — | FAPI precursor Huayi | 41209215 2025 Quant Imaging Med Surg |
| — | — | — | — | — | — | 41129212 2025 JCI Insight |
| — | — | — | — | — | — | 41034790 2025 BMC Cancer |
| — | — | — | — | — | — | 40809416 2025 Front Med (Lausanne) |
| — | — | SPE | — | exceeding 98% | FAPI-04 MedChemExpress | 40484962 2025 Cancer Imaging |
| — | — | — | — | — | — | 40278857 2025 Eur J Nucl Med Mol Imaging |
| — | — | — | — | — | — | 40263181 2025 Mol Diagn Ther |
| — | — | — | — | — | — | 40263181 2025 Mol Diagn Ther |
| — | — | — | — | — | — | 40213671 2025 Theranostics |
| — | — | — | — | — | — | 40076605 2025 Int J Mol Sci |
| FASTlab 2 GE HealthCare | custom manifold | none | — | 98.77 ± 0.12 | DOTA-FAPI-04 MedChemExpress | 39598846 2024 Molecules Automated labeling of the precursor was accomplished using a FASTLab 2 synthesizer. |
| Modular-Lab Standard Eckert & Ziegler | fixed tubing | SPE | 85.5±1.4% no | 99.6±0.2% | DOTA-FAPI-4 MedChemExpress | 39050235 2024 Asia Ocean J Nucl Med Biol Automated radiosynthesis module (Modular-Lab Standard) was from Eckert & Ziegler, Germany. — [68Ga]Ga-FAPI-4 ... were found to be ... (85.5±1.4)% (n=9) |
| — | — | — | — | — | FAPI-04 | 41946434 2026 J Control Release |
| — | — | — | 97.47 ± 0.26% yes | 99.18 ± 0.34% | FAPI-4 | 42705038 2026 Appl Radiat Isot a commercial fixed tubing (non-cassette) based automated module namely Eckert and Ziegler 'Modular-Lab Standard' (EZ-ML) — decay corrected (dc) radiochemical yield (RCY) and radiochemical purity (RCP) of 97.47 ± 0.26% and 99.18 ± 0.34% respectively |
| — | — | — | — | — | — | 42663571 2026 Rheumatology (Oxford) |
| — | — | — | — | — | — | 42660633 2026 J Nucl Med |
| — | — | — | — | — | — | 42410759 2026 Clin Nucl Med |
| — | — | — | — | — | FAPI-04 | 42343548 2026 J Med Chem |
| — | — | — | — | — | — | 42273741 2026 Circ Cardiovasc Imaging |
| — | — | — | — | — | — | 42128000 2026 Br J Radiol |
| — | — | — | — | — | — | 42113378 2026 Ann Surg Oncol |
| — | — | — | — | — | — | 42007813 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41887115 2026 Bioorg Chem |
| — | — | — | — | — | — | 41771036 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41738886 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41649855 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41627842 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41544061 2026 Clin Nucl Med |
| — | — | — | — | — | FAPI-04 | 35658448 2022 J Med Chem |
Precursor
- Common precursor
- DOTA-FAPI-04 precursor PMID 35991604 (DOI 10.3389/fchem.2022.939160)
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Huayi, MCE, MedChemExpress
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [68Ga]Ga-FAPI-04, or handle the enquiry for you.
Get in touchQuality control Derived from the published synthesis
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator-produced per synthesis data (PMID 35991604) -> Ge-68 breakthrough; receptor ligand with a saturable target -> molar activity (rule); organic solvent confirmed in synthesis data (PMID 35991604) -> GC residual solvents
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-FAPI-04.
Get in touchNotes
Added from reverse module search (stage 6); 9 article(s) with Ga-68.